Hemosol B0 (Calcium, Lactic Acid, Magnesium, Sodium, Chloride Ion, Hydrogen Carbonate)

Hemosol B0 is primarily employed in clinical settings where precise electrolyte and acid‑base management is required.

• Maintenance of electrolyte concentrations during haemodialysis.
• Correction of mild metabolic acidosis in patients receiving renal replacement therapy.
• Support of calcium and magnesium balance in critically ill patients.
• Provision of sodium and chloride to stabilize plasma osmolality.
• Use as a compatible carrier solution for intravenous drug admixtures.

Adverse reactions to Hemosol B0 are generally infrequent, but they can be categorized by frequency and severity.

Common

• Mild infusion site irritation or erythema.
• Transient nausea or vomiting.
• Slight increase in serum calcium or magnesium levels.
• Temporary headache or dizziness.

Serious

• Severe hypercalcemia or hypermagnesemia.
• Rapid shifts in blood pH leading to metabolic alkalosis.
• Anaphylactic or severe hypersensitivity reactions.
• Pulmonary edema from fluid overload.

When using Hemosol B0, clinicians should observe several precautionary measures to minimize risk.

• Verify patient electrolyte and acid‑base status before initiation.
• Adjust infusion rate in patients with cardiac or renal impairment.
• Monitor serum calcium, magnesium, and bicarbonate levels during therapy.
• Avoid use in patients with known hypersensitivity to any component.
• Use caution in pregnant or lactating individuals until safety is established.
• Ensure compatibility with other intravenous solutions to prevent precipitation.

Hemosol B0 may interact with other medications or solutions; awareness of these interactions helps maintain safety.

Avoid

• Concurrent administration with calcium channel blockers that may exacerbate hypercalcemia.
• Co‑infusion with high‑dose bicarbonate solutions, which can cause excessive alkalosis.
• Use with blood products containing citrate, increasing risk of electrolyte imbalance.

Use with caution

• Loop diuretics, which can alter calcium and magnesium excretion.
• ACE inhibitors or ARBs, where shifts in sodium and potassium may affect blood pressure control.
• Anticoagulants used during haemodialysis, requiring monitoring of clotting parameters.